Strong Revenue and Earnings Growth
Sales grew 8% as reported and in constant currency. Instruments grew 6%, and recurring revenue grew 9%. Non-GAAP earnings per share rose by 16% to $3.40.
Pharma and Regional Performance
Pharma segment grew 11%, with notable growth in the Americas and Asia regions. China showed particularly strong growth with more than 20% increase in pharma sales.
Product Innovation and Adoption
Launch of Xevo CDMS and strong growth in Xevo TQ Absolute platforms. New products launched over the past 5 years grew approximately 50% in the quarter.
Guidance Increase
Full-year 2025 guidance raised to 6.7% to 7.3% constant currency sales growth, and adjusted earnings per share guidance increased to $13.05 to $13.15.
Combination with BD's Bioscience & Diagnostic Solutions
Expected to complete around the end of Q1 2026, with plans for synergy realization and value creation.